Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

InflaRx's Stock Gains Following FDA Fast Track Status To Skin Disease Drug

The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ:IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).

The FDA grant was supported by the positive data readout in pyoderma gangrenosum (PG) from its Phase 2a open-label dose-escalation study.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.